Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

434 Features
Movers and Shakers of the Pharma Industry - David Mitchell

08 Aug 06

David Mitchell is the Commercial Director at McNeil Consumer Healthcare, a company that produces remedies for self-treatment available at pharmacies and supermarket stores.
Freya Eden-Ellis

Movers and Shakers of the Pharma Industry - Alex Bishop

08 Aug 06

Alex Bishop is the IT Business Manager at Pfizer, the largest supplier of medicines to the NHS.
Freya Eden-Ellis

Diverse challenges await generics industry

04 Aug 06

Because of the ever-increasing costs of healthcare provision the world over, many governments are enacting legislation to promote generic prescription in order to keep costs down. With drugs worth $160 billion in sales coming off patent by 2015, it would seem a good time to be in the generics industry. However the generics market is not without challenges.
Datamonitor

Lean Documentation 4

03 Aug 06

Manufacturing Instructions and Records: Operators are expected to follow manufacturing instructions to produce a product that meets the required specification. Typically these instructions will be written by technical experts, the chemical engineers who were responsible for the technology transfer, the process validation and so on.
PharmiWeb.com Field Reporter: Joanna Hills

Networking Tips

03 Aug 06

Networking: What is it and How do you do it?
Jim Melling - Field Reporter

Elidel Eczema Cream: Dr Mark Ballard Answers Our Questions

01 Aug 06

Dr Mark Ballard, the Medical Director of Respiratory and Dermatology Therapeutic Areas at the Novartis Pharmaceuticals Corporation answers our questions about their eczema cream Elidel.
Freya Eden-Ellis

Call for guidelines on when to stop or continue drug treatment for Alzheimer’s Disease

01 Aug 06

Doctors taking part in a survey on Alzheimer’s Disease (AD) management have called for clear and consistent guidelines on diagnosis and treatment of the condition to be drawn up as a matter of urgency. The survey was sponsored by Eisai Europe Ltd and Pfizer Inc, who market the cholinesterase inhibitor Aricept (donepezil), and was presented during the International Conference on Alzheimer’s Disease and Related Disorders.
Olwen Glynn Owen – Pharmiweb Field Reporter

Antiarrhythmics: RSD1235 woes reduce market potential but not clinical impact

31 Jul 06

Atrial fibrillation (AF) is the most common form of arrhythmia, or irregular heartbeat, with an estimated nine million sufferers worldwide. Although safe, effective treatment for AF is critical, historically there has been little R&D investment and little innovation in the AF market. However, this may be about to change, with the AF market expected to triple by 2015.
Datamonitor

PowderMed: flying ahead in avian flu

21 Jul 06

PowderMed has submitted an application to UK regulators seeking to conduct human trials of its avian influenza vaccine. Developing an effective vaccine against the next influenza pandemic is a challenging task, but one many companies are taking on. However, until a virus able to cause a pandemic emerges, no one knows for certain which product will be most effective.
Datamonitor

Role of Arenesp and cinacalcet in protecting hearts of renal patients

20 Jul 06

Treatment of chronic kidney disease (CKD) is focussing increasingly on prevention of cardiovascular complications with the aim of reducing the cardiovascular mortality and morbidity to which many patients currently succumb.
Olwen Glynn Owen - PharmiWeb Field Reporter

Hints and Tips: Survive in the Work Place Part Two

19 Jul 06

Hints and Tips: Survive in the Work Place Part Two
Elaine Ford - PharmiWeb Field Reporter

Urinary incontinence: common problem, not commonly reported

13 Jul 06

Despite not being a widely acknowledged affliction, urinary incontinence (UI) is a relatively common condition, with up to 23% of the female population suffering from one form alone. Yet despite the significant impact UI can have on the quality of life of the sufferers, according to a new report, approximately half of sufferers neither seek treatment nor report the problem to a physician.
Datamonitor

Baraclude (entecavir) offers much-needed new option for chronic hepatitis B infection

11 Jul 06

Baraclude (entecavir), a new oral drug developed by Bristol-Myers Squibb, recently approved by the European Commission for treatment of chronic hepatitis B viral (HBV) infections, is expected to become available in a few months in some countries of the EU, the Middle East and Africa.
Olwen Glynn Owen - PharmiWeb Field Reporter

Tibotec and J&J cleared to launch Aptivus rival

11 Jul 06

The FDA has approved Tibotec and Johnson & Johnson's HIV drug Prezista, enabling it to join Boehringer Ingelheim's recently launched Aptivus as one of just two second-generation protease inhibitors currently available. However, competition will be fierce as both drugs target similar patients in a crowded market where small differences in marketing approaches could impact hugely on sales.
Datamonitor

New data results for Roche cancer drug Xeloda impressive

10 Jul 06

ROCHE is set to file for a new indication for its oral, targeted cancer drug Xeloda® following impressive new data presented at the American Society of Clinical Oncology conference (ASCO).
Rhonda Siddall,

Lean Documentation 1: GLP, GCP, GMP, SOP, too many documents ?

09 Jul 06

Pharmaceutical companies are renowned for exhaustive pages of regulatory reports and documentation procedures. An enormous amount of effort goes into creating and maintaining these documentations, usually by people for whom it is only a small part of their job. Another problem is that complexity exists in such documents and may be due to an excess of information or to inappropriate structure. Again, historically there may have been a drive to put every little detail into the procedures, in t
PharmiWeb Field Reporter -Joanna Hills

Biomarin advance novel antihypertensive...Researchers identify novel molecular target for the treatment of sepsis

07 Jul 06

Todays Headlines from across the DailyUpdates network (July 7th, 2006) - In today's edition we highlight Biomarin's development of the novel antihypertensive 6R-BH4 and new research describing a promising molecular target for future sepsis therapeutics.
LeadDiscovery

Phase 2 testing commences on Abiogen's anxiolytic ABIO 0801...Novel drug delivery technology facilitating the use of therapeutic macromolecules

05 Jul 06

Todays Headlines from across the DailyUpdates network (from DailyUpdates 5th July)- Although press releases are quite thin on the ground today because of the July 4th holiday in the US, Abiogen have released important information regarding the start of phase 2 testing of the company's anxiolytic, ABIO 08/01. In addition we feature a review describing a potentially groundbreaking drug delivery technology. This technology harnesses protein transduction domains (PTDs), endogenous peptide sequences
LeadDiscovery

Biologics driving growth to 2010

29 Jun 06

The leading pharmaceutical companies have historically focused on developing small molecules to drive their bottom line growth. However, this is set to change, with around 60% of revenue growth for 'Big Pharma' companies forecast to come from biologic products. In fact by 2010, annual sales of biologics will have increased by $26 billion, compared to a $13 billion increase for small molecules.
Datamonitor

New clinical data on Vasogen's heart failure candidate...Johnson and Johnson publish on potential asthma candidate

27 Jun 06

Todays Headlines from across the DailyUpdates network - Today we feature news from Vasogen on their candidate treatment of chronic heart failure plus new data from Johnson & Johnson on a new integrin antagonist that may underly a future treatment of asthma
LeadDiscovery

Depression sufferers still reluctant to see physician

27 Jun 06

While the number of individuals with major depressive disorder (MDD) is set to grow only minimally in next two decades, the condition still represents a key health risk, for both society and the individual. For example, MDD is a leading cause of disability and under-diagnosis remains a problem. Furthermore, the leading classes of MDD drugs have been linked to increased suicidality.
Datamonitor

ArQule moves forward with their cell cycle modulator...Wyeth develops selective GABA(A) alpha2/alpha3 subtype agonists as candidate anxiolytics

21 Jun 06

Todays Headlines from across the DailyUpdates network (20th June, 2006): We highlight research from Merck who are developing a novel approach to anxiety and news from ArQule on their oncology candidate
LeadDiscovery

Micromet develops new lymphoma therapeutic...KD-247, a promising HIV-neutralizing antibody

20 Jun 06

Todays Headlines from across the DailyUpdates network (19th June - 2006): Today we feature over 60 breaking journal articles including our featured study discussing the development of a new antibody being developed for HIV-1. In addition we highlight news from Micromet on their antibody therapy for the treatment of NHL
LeadDiscovery

Cell Therapeutics' Xyotax holds much promise for few patients

19 Jun 06

Cell Therapeutics has announced positive phase III data for Xyotax in non-small cell lung cancer, with the drug significantly increasing survival in pre-menopausal female patients with high estrogen levels. However, with such a limited patient population, Xyotax will struggle to compete with Sanofi-Aventis' Taxotere, Eli Lilly's Gemzar and genericized paclitaxel in cost-constrained markets.
Datamonitor

CD40:CD40L as a target for Alzheimers...A new candidate oncology therapeutic to enter the clinic

19 Jun 06

In today's edition of DailyUpdates we report on CD40:CD40L. Traditionally a target for autoimmune/transplant therapeutics, we highlight a study supporting the development of blockers of CD40:CD40L as candidate treatments of Alzheimer's disease. We also highlight a new oncology candidate in development by Lorus
LeadDiscovery

Further development of HDAC inhibitors...Novel approaches to the treatment of depression

16 Jun 06

In today's edition of DailyUpdates we headline with news from CuraGen and TopoTarget on a new trial evaluating the combination of an HDAC inhibitor an cis-retinoid acid. In addition we highlight research from Wyeth suggesting a new approach to depression
LeadDiscovery

Erbitux: emerging data at ASCO reveal potential to further exploit benefits of the targeted EGFR therapy in mCRC

14 Jun 06

Data presented at the American Society of Clinical Oncology (ASCO) meeting in Atlanta this month suggest that administering the epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetuximab) fortnightly rather than weekly in metastatic colorectal cancer (mCRC) is a feasible option. Another study probing whether scaling up the dose, to the point where patients experience the significant rash linked to long survival, achieves a better response, shows high doses are well tolerated.
Olwen Glynn Owen - PharmiWeb Field Reporter

Vertex: next-generation hepatitis drugs within reach

12 Jun 06

Vertex has launched a major phase II clinical trial to test a new hepatitis C drug candidate, with a second trial scheduled to begin in June. This is a significant advance in the development of much-needed treatments for hepatitis C. By drawing parallels with similar HIV treatments, Datamonitor's Morris Paterson outlines the pitfalls and prospects for this new drug.
Datamonitor Expert Views

Advances in diabetes...combating the menace of HIV/Tuberculosis co-infection

12 Jun 06

Today's edition highlights news from Metabolex announcing the initiation of a Phase 2/3 trial of a novel insulin sensitizer, metaglidasen. In addition we discuss research published by Advanced Life Sciences who are making exciting breakthroughs moving towards the treatment of HIV Tuberculosis co-infection which has become a global catastrophe.
LeadDiscovery

Targeting Ubiquitin For Drug Discovery & Development

10 Jun 06

Breakthroughs in our understanding of the Ubiquitin system are increasingly being routed towards clinical applications. Targeting Ubiquitin for Drug Discovery and Development conference has assembled leaders from industrial and academic research to discuss the state of the art and prospects for the future. With the FDA approval and commercialization of Velcade, scientists are now beginning to see the potential of this ever expanding science. New therapeutic targets are being explored and implica
Seth Fritts

Advertising